Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022)-Reference-Cited by-同舟云学术

Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022)

Published:2024-06 Issue: Volume:4 Page:100039
ISSN:2949-8201
Container-title:ESMO Real World Data and Digital Oncology
language:en
Short-container-title:ESMO Real World Data and Digital Oncology

Author:

Derksen J.W.G.^ORCID,Martins-Branco D.^ORCID,Valachis A.^ORCID,Pellat A.^ORCID,van Nassau S.C.M.W.^ORCID,Aggarwal A.^ORCID,Pentheroudakis G.^ORCID,Koopman M.^ORCID,Castelo-Branco L.^ORCID,Delaloge S.^ORCID

Funder

European Society for Medical Oncology

Publisher

Elsevier BV

Reference36 articles.

1. Observational research, randomised trials, and two views of medical science;Vandenbroucke;PLoS Med,2008

2. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response;Eichler;Nat Rev Drug Discov,2011

3. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results;Kennedy-Martin;Trials,2015

4. Disparity in the selection of patients in clinical trials;Habibzadeh;Lancet,2022

5. Real-world data for regulatory decision making: challenges and possible solutions for europe;Cave;Clin Pharmacol Ther,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development;Annals of Oncology;2024-08